ClinicalTrials.gg

Program

belvarafenib

Also written as “Belvarafenib”, “HM95573, cobimetinib” and “HM95573, cetuximab”.

Its studies are mostly in Melanoma · Neoplasm Metastasis · Neoplasms, led by 2 companies.

Furthest: phase 2, since Feb 27, 20266 company-led studies, 4 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hanmi Pharmaceutical42 open or runningphase 2since Feb 27, 2026Jan 15, 2015Sep 2029phase 2 · NCT07449754
Hoffmann-La Roche22 open or runningphase 2since Oct 11, 2020Oct 11, 2020Dec 31, 2026phase 1 · NCT04835805

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 15, 2015First study: phase 1 study in NeoplasmsNew to Hanmi PharmaceuticalHanmi Pharmaceutical · NCT02405065 · 72 enrolled · Korea, Republic of
  2. Mar 20, 2017Phase 1 study in Solid TumorHanmi Pharmaceutical · NCT03118817 · 65 enrolled · Korea, Republic of
  3. Aug 7, 2017Phase 1 study in Neoplasm MetastasisHanmi Pharmaceutical · NCT03284502 · 148 enrolled · Korea, Republic of
  4. Oct 11, 2020Hoffmann-La Roche's first study: phase 2 study in Solid TumorsNew to Hoffmann-La RocheHoffmann-La Roche · NCT04589845 · 920 enrolled · United States, Australia, Belgium and more
  5. Apr 6, 2021Phase 1 study in MelanomaHoffmann-La Roche · NCT04835805 · 65 enrolled · United States, Australia, Canada and more
  6. Feb 27, 2026Phase 2 study in MelanomaPhase 2 reachedHanmi Pharmaceutical · NCT07449754 · 45 planned · South Korea

Ahead

  1. Dec 31, 2026Primary completion: phase 1 study in MelanomaHoffmann-La Roche · NCT04835805
  2. Sep 2029Primary completion: phase 2 study in MelanomaHanmi Pharmaceutical · NCT07449754
  3. Sep 25, 2032Primary completion: phase 2 study in Solid TumorsHoffmann-La Roche · NCT04589845

TargetBeta

“RAF serine/threonine protein kinase inhibitor”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
tovorafenibruleday-one-biopharmaceuticals-incphase 38

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07449754Melanoma · South Korea2RecruitingHanmi PharmaceuticalSep 202945
NCT04835805Melanoma · United States, Australia, Canada and more1Active, not recruitingHoffmann-La RocheDec 31, 202665
NCT04589845Solid Tumors · United States, Australia, Belgium and more2Active, not recruitingHoffmann-La RocheSep 25, 2032920
NCT03284502Neoplasm Metastasis · Korea, Republic of1Active, not recruitingHanmi PharmaceuticalSep 30, 2024148
NCT03118817Solid Tumor · Korea, Republic of1CompletedHanmi PharmaceuticalFeb 4, 202065
NCT02405065Neoplasms · Korea, Republic of1CompletedHanmi PharmaceuticalJan 18, 201772

How it is read

Names in the registry

  • “Belvarafenib”, 3 entries
  • “HM95573, cobimetinib”, 2 entries
  • “HM95573, cetuximab”, 2 entries
  • “HM95573”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.